Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma

Inclusion Criteria

• •1. aged 18-75 years;
• •2. histologically or cytologically proven diagnosis of pancreatic adenocarcinoma;
• •3. treatment-naive locally advanced pancreatic cancer (locally advanced status was determined by our multidisciplinary team based on the National Comprehensive Cancer Network definitions);
• •4. no distant metastasis as defined by CT or MRI of the chest, abdomen and pelvis;
• •5. at least 1 measurable lesion based on the Response Evaluation Criteria in Solid Tumors criteria (RECIST) 1.1;
• •6. an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1;
• •7. adequate hematological, liver, renal function:
• •1. absolute neutrophil count≥1500 cell/mm3;
• •2. platelet count≥100×109/L;
• •3. hemoglobin concentration \>90 g/L;
• •4. albumin≥30 g/L ;
• •5. total bilirubin\<1.5 times the upper limit of normal;
• •6. alanine aminotransferase and aspartate aminotransferase≤3 times the upper limit of normal;
• •7. serum creatinine concentration\<1.5 times the upper limit of the normal range or less and creatinine clearance rate≥45 mL/min;
• •8. life expectancy of at least 3 months.